1Cavo M, Baccarani M. The changing landscape of myeloma therapy. N Engl J Med 2006;354:1076-8.
2Kumar SK, Raikumar S:; Dispenzieri A, et al. Improved survfval in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20.
3Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Frangais du My6lome. N Engl J Med 1996;335:91-7.
4Koreth J, Cutler CS, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007;13:183-96.
5Fermand JP, Ravaud P, Chevret S, et al. High-dose therapyand autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998;92:3131-6.
6knderson KC, )dsina M, Bensinger V:7, et al. NCCN clinical practice guidelines in oncologEv: multiple myeloma. J Natl Compr Canc Netw 2009;7:908-42.
7Dunavin NC, \,Vei L, Elder R et al. Early versus delayed autologous stern cell transplant in patients receiving novel therapies for multiple myeloma. Leuk I:ymphoma 2012. nf" nrintl.
8Kumar SK, Lacy MQ, Dispenzieri A, et al, Early versus delayed autologous transplantation after immunomodulatolT agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer 2012;118:1585-92.
9Eom HS, Min CK, Cho BS, et al. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma. Jpn J Clin Oncol 2009;39:449-55.
10Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010;28:4621-9.
